Solvay Pharmaceuticals, Gmbh

Dania B Reiche

Jochen Antel

Michael Firnges

Uwe Schoen

Holger Sann

Daniel Jasserand

Peter-Colin Gregory

Samuel David

Reinhard Brueckner

Ulf Preuschoff

Harald Waldeck

Michael Wurl

Christian Eeckhout

Josephus Hubertus Maria Lange

Bartholomeus J Van Steen

Uwe Schön

Uwe Reinecker

Matthias Mentzel

Reinhard Brückner

The present invention relates to novel N-sulfamoyl-piperidineamides of Formula I and their physiologically acceptable acid addition salts, to pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment of obesity and its concomitant and/or secondary diseases and related or other conditions. 

N-sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions

Described herein are pharmaceutical compositions comprising therapeutically effective quantities of (i) a Kchannel modulator; and (ii) a CBmodulator. Also described herein are methods of making and using these compositions.

Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators

3-cyanonaphthalene-1-carboxylic acid perhydroxyalkylmethyl-piperazine compounds of formula I which are antagonistic to tachykinin receptors, pharmaceutical compositions containing such compounds, methods of using such compounds for the treatment and/or inhibition of various diseases and disorders, processes for preparing such piperazine compounds, and intermediate products of these processes.

NK1 and NK2-antagonists and compositions and methods of using the same

N-sulfamoyl-N'-benzopyranpiperidine compounds of formula I and their physiologically acceptable acid addition salts, pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment and/or inhibition of glaucoma, epilepsy, bipolar disorders, migraine, neuropathic pain, obesity, type II diabetes, metabolic syndrome, alcohol dependence, and/or cancer, and related concomitant and/or secondary diseases or conditions 

N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof

The invention relates to a group of hydronopol derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel hydronopol derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved. The invention relates to compounds of the general formula (1) wherein the symbols have the meanings as given in the description.

Hydronopol derivatives as agonists on human ORL1 receptors

1-&lsqb;1-(hetero)aryl-1-perhydroxyalkylmethyl&rsqb;-piperazine compounds, process for their preparation and pharmaceutical compositions containing them

Growing community of inventors

Hannover, Germany

Dania B Reiche